Gestational trophoblastic neoplasia secondary prevention: Difference between revisions
No edit summary |
Mahshid |
||
Line 14: | Line 14: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gynecology]] | |||
[[Category:Surgery]] |
Revision as of 23:37, 26 November 2017
Gestational trophoblastic neoplasia Microchapters |
Differentiating Gestational trophoblastic neoplasia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Gestational trophoblastic neoplasia secondary prevention On the Web |
American Roentgen Ray Society Images of Gestational trophoblastic neoplasia secondary prevention |
FDA on Gestational trophoblastic neoplasia secondary prevention |
CDC on Gestational trophoblastic neoplasia secondary prevention |
Gestational trophoblastic neoplasia secondary prevention in the news |
Blogs on Gestational trophoblastic neoplasia secondary prevention |
Directions to Hospitals Treating Gestational trophoblastic neoplasia |
Risk calculators and risk factors for Gestational trophoblastic neoplasia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2]
Overview
Careful monitoring after the removal of hydatidiform mole or termination of pregnancy can lead to early diagnosis of a choriocarcinoma, which improves outcome.
=Secondary Prevention
Careful monitoring after the removal of hydatidiform mole or termination of pregnancy can lead to early diagnosis of a choriocarcinoma, which improves outcome.